A public-health agency is choosing between building a custom summarization model or buying a vendor's GenAI tool to condense outbreak reports for the public-health director. What tradeoff should weigh most heavily in this decision?

The build-versus-buy tradeoff for a GenAI use case should weigh whether the task is generic enough that an existing vendor tool already handles it well, against whether the agency has the sustained technical capacity and a specialized enough need to justify the investment of building custom. Summarizing outbreak reports is a fairly general text-condensation task, which tends to favor a vendor tool's faster time-to-value over the longer timeline and ongoing maintenance a custom build requires. Claiming custom building is always better because it guarantees ownership overstates what ownership buys; owning a model that underperforms a mature vendor tool, while also consuming staff time to maintain, isn't automatically the stronger outcome. Asserting vendor tools never need internal evaluation is a real risk in the opposite direction, since even a purchased GenAI tool still needs review for accuracy on public-health-specific terminology and for how it handles sensitive outbreak data. Basing the decision on whichever option the vendor's materials happened to mention first replaces an actual tradeoff analysis with whatever a sales pitch emphasized, which isn't a real decision criterion at all. Before finalizing either path, the agency should pilot the vendor tool on a handful of real outbreak reports and check its summaries against a public-health reviewer's judgment, since accuracy on domain-specific terminology is often where a general-purpose tool falls short.